SANASana Biotechnology, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.92 · now $2.92 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, SANA has typically landed between $1.92 and $4.66 — a range of −34.4% to +59.7% from the issuance price $2.92.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,388 overlapping 1 month windows · 2021-02-042026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.92) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where SANA has typically landed a month from the 2026-09-16 close of $2.92 — the range is history, not a prediction.

$1.92worst · -34.4%$4.66best · +59.7%
  • now $2.92 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.75 (-5.9%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.25$3.24
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.92$4.66
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,388 windows spanning 2021-02-04 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-01-04−50.4%−50.4%+0.0%
2022-01-03−48.8%−49.0%+0.0%
2021-12-23−48.0%−48.0%+0.0%
3 best
2024-12-19+111.2%+0.0%+141.2%
2024-12-23+109.2%−1.2%+136.8%
2024-12-18+106.5%−5.3%+128.4%

1,388 overlapping windows · 2021-02-042026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
80%
+22.6%
n=5
Feb
20%
+2.6%
n=5
Mar
33%
−7.0%
n=6
Apr
50%
+5.8%
n=6
May
50%
−3.8%
n=6
Jun
50%
+3.7%
n=6
Jul
50%
+5.8%
n=6
Aug
50%
+6.5%
n=6
Sep
17%
−14.2%
n=6
Oct
20%
−2.2%
n=5
Nov
20%
−3.8%
n=5
Dec
20%
−17.1%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$6$3↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-01-08FMR LLCotherSale164,912 @ $6.71$1.1M−3.5% of holding+63.3%+149.0%4,542,511Form 4 · filed 2 days after the trade
2025-01-08FMR LLCotherSale100,000 @ $6.11$611K−2.1% of holding+63.3%+149.0%4,732,423Form 4 · filed 2 days after the trade
2025-01-08FMR LLCotherSale25,000 @ $6.50$163K−0.5% of holding+63.3%+149.0%4,707,423Form 4 · filed 2 days after the trade
2025-01-08FMR LLCotherSale1,000 @ $7.26$7K−0.0% of holding+63.3%+149.0%4,541,511Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

85 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-27PATEL DHAVALKUMAR DHIRAJLALofficerWithheld for tax41,158183,352Form 4
2026-08-26PATEL DHAVALKUMAR DHIRAJLALofficerOption exercise125,000224,510Form 4
2026-08-26PATEL DHAVALKUMAR DHIRAJLALofficerOption exercise125,000250,000Form 4
2026-07-06Bishop Hans EdgardirectorAward / grant6,2975,854,800Form 4
2026-06-04NELSEN ROBERTdirectorAward / grant90,00090,000Form 4
2026-06-04REICIN ALISEdirectorAward / grant90,00090,000Form 4
2026-06-04Rosiello Robert L.directorAward / grant90,00090,000Form 4
2026-06-04Yang Patrick YdirectorAward / grant90,00090,000Form 4
2026-06-04Seitz MichelledirectorAward / grant90,00090,000Form 4
2026-06-04Mulligan RicharddirectorAward / grant90,00090,000Form 4
2026-06-04Bishop Hans EdgardirectorAward / grant90,00090,000Form 4
2026-06-04Bilenker Joshua H.directorAward / grant90,00090,000Form 4
2026-04-06Bishop Hans EdgardirectorAward / grant7,7635,848,503Form 4
2026-03-09Harr StevedirectorWithheld for tax12,8197,944,251Form 4
2026-03-09Harr StevedirectorWithheld for tax11,5267,957,070Form 4
2026-03-09Wyrick Susan D.officerWithheld for tax3,342197,241Form 4
2026-03-09Wyrick Susan D.officerWithheld for tax1,045196,196Form 4
2026-03-07Wyrick Susan D.officerOption exercise3,250200,583Form 4
2026-03-07Harr StevedirectorOption exercise50,0007,968,596Form 4
2026-03-07Wyrick Susan D.officerOption exercise3,2506,500Form 4
2026-03-07Harr StevedirectorOption exercise50,000100,000Form 4
2026-03-06Wyrick Susan D.officerOption exercise10,416197,333Form 4
2026-03-06Wyrick Susan D.officerOption exercise10,41631,251Form 4
2026-03-06Harr StevedirectorOption exercise41,6667,918,596Form 4
2026-03-06Harr StevedirectorOption exercise41,666125,001Form 4
2026-03-05Wyrick Susan D.officerAward / grant45,83345,833Form 4
2026-03-05Harr StevedirectorAward / grant900,000900,000Form 4
2026-03-05Harr StevedirectorAward / grant200,000200,000Form 4
2026-03-05Wyrick Susan D.officerAward / grant206,250206,250Form 4
2026-03-03Wyrick Susan D.officerWithheld for tax491186,917Form 4
2026-03-02Wyrick Susan D.officerOption exercise1,5251,525Form 4
2026-03-02Wyrick Susan D.officerOption exercise1,525187,408Form 4
2026-02-17Piper BrianofficerAward / grant200,000200,000Form 4
2026-02-17Piper BrianofficerAward / grant900,000900,000Form 4
2026-01-05Wyrick Susan D.officerWithheld for tax2,407185,883Form 4
2026-01-05Bishop Hans EdgardirectorAward / grant6,1575,840,740Form 4
2026-01-02Wyrick Susan D.officerOption exercise7,500188,290Form 4
2026-01-02Wyrick Susan D.officerOption exercise7,5000Form 4
2026-01-02Wyrick Susan D.officerOption exercise7,5000Form 4
2025-12-15Wyrick Susan D.officerWithheld for tax873180,790Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.